ClinicalTrials.gg
RecruitingNCT06828679Updated Dec 22, 2025

Using AI Systems to Optimize the Clinical Outcome of Stroke Patients

An interventional study of Acupuncture and control group in Acute Stroke Intervention, Acute Stroke and Acute Ischemic Stroke, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 65 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Ischemic Stroke by Chinese University of Hong Kong — 7 open to participants now, 7 under way, none of them phase 3. Ischemic Stroke · Chinese University of Hong Kong.

Started
2025
the only one that year
No phase
2 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies in Ischemic Stroke by Chinese University of Hong Kong, this one is the only one that started in 2025, is one of 2 with no phase, and was the 13th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 13 studies in Ischemic Stroke by Chinese University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 65 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Ischemic Stroke by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

This project addresses the imminent challenge of providing adequate motor rehabilitation to a growing number of stroke survivors amidst the ageing population, decreasing age of stroke, and shortage of physical/occupational therapists in Hong Kong through AI and precision rehabilitation. To reduce the socioeconomic burden from the stroke survivors' loss of independence and their care (>HK$15 billion/year), the efficacy of rehabilitation and efficiency of its delivery must be improved. These goals can be achieved by prescribing them with individually tailored rehabilitations predicted to yield maximal functional return. Defining a predictive model for such personalization remains challenging given the immense heterogeneity of stroke. The investigators aim to build an explainable AI system that predicts a subject's recovery potential and the treatment option that may realize this potential based on multi-modal pre-rehab assessments. Data from clinical, neuroimaging, neurophysiological, and multi-omic evaluations will be collected from stroke survivors (N≥400) before they undergo upper limb rehab with usual care, neuromuscular stimulation, robotic training, or acupuncture. Machine learning-extracted data features will be used to train decision-tree and neural-network AI algorithms for robust predictions. As soon as the model is validated, the investigators will deploy it to implement a personalized rehab program in the community. Our model's ability to predict the optimal intervention from a wide spectrum of input modalities distinguishes ours from previous less-than-accurate models. Our interdisciplinary team of 13 PIs with expertise in neurology, PT/OT, acupuncture, electrical/biomed. engineering, robotics, neuroscience, neuroimaging, multi-omics, data science, and clinical trial management will put us in a world-unique position to execute this project successfully and generate opportunities of interdisciplinary education. In the long run, our prediction system will accelerate marketization of new rehab strategies by facilitating their clinical-trial evaluations in more targeted subjects, thereby leading Hong Kong to be a future global hub of innovative rehabilitation.

Read the detailed description

DELIVERABLE 1: Overview of Data Collection Plan. Subacute stroke survivors (N=400) will be recruited and randomly assigned to one of four groups, which will receive usual rehab care only, and usual care plus acupuncture, robotic, or neuromuscular electrical stimulation (NMES) training, respectively. Each subject will be evaluated before (A0), after (A1) and 6 months after the start of intervention (A2). At A0, thorough clinical, neurophysiological (EEG, EMG, TMS), MRI, and blood-based assessments will be made for deriving predictive recovery markers. At A1 and A2, only the clinical scores and EMG will be assessed for characterizing post-rehab functional gain and long-term recovery. Also, in all groups clinical scores will be recorded midway through intervention (A½) to monitor treatment progress. Treatments will last ≥1 month with ≥20 training sessions. All A0, A1, and A2 data will be analyzed offline with machine learning and other methods, and then used to train the AI model, PRAISE-HK (Precision Rehabilitation AI System for Enhancing recovery in Hong Kong and beyond).

DELIVERABLE 2: Explainable AI Models of Recovery. Overview. Our AI system receives high-dimensional data inputs from diverse modalities, each of which requires unique processing techniques tailored to the specific characteristics of the data type for analysis. Neuroimaging data, for instance, demand specialized image processing algorithms for deriving brain structural and functional measures, while time series data such as EEG and EMG must first be analyzed with signal processing tools that capture embedded patterns across varying temporal resolutions. The need for domain-specific preprocessing of diverse data types engenders a level of analytic complexity that defies standard deep learning techniques, which may not accommodate the unique challenges presented by each modality. To obtain actionable, clinically relevant insights while ensuring interpretability and integration of the multimodal data, more sophisticated algorithms beyond standard deep learning are needed.

As such, the investigators propose the construction of a sophisticated AI fusion model as the core of PRAISE-HK. Fusion model is a machine learning approach that integrates input features from multiple data modalities in a way that leverages their unique contributions to make a prediction more accurate and robust than any single modality could produce. Although the number of subjects here (N=400) is, to the best of our knowledge, the highest among all similar studies, for high-dimensional data this number is small enough to impose rather stringent constraints on the choice of analytical methods should overfitting be avoided, and model generalization ensured. With these considerations, the investigators will construct our fusion model in two phases. Phase 1 involves extraction of predictors from the individual modalities through their independent processing with domain-specific AI models. This phase is necessary since each modality can yield the most valuable information only with distinct processing pipelines. Phase 2 involves the fusion of these processed modalities. The investigators will formulate a specialized fusion model that accommodate the relatively small sample size, the predictors' high dimensionality, and potential instances of missing data. The final model will capitalize on the strengths of the domain-specific phase-1 outputs and combine their insights for improved prediction accuracy.

Phase 1: Modality-specific Feature Extractions. For the neuroimaging and multi-omics modalities, the investigators will leverage pre-trained models to map high-dimensional inputs to a reduced set of informative features or embeddings. The investigators will start by fine-tuning foundation models based on each dataset, and then develop modality-specific models using the pre-trained and fine-tuned foundation models as feature extractors. For time-series data such as EMG, EEG, and motion capture data, both standard and custom-derived procedures will be used to filter noise and identify suitable predictors. From the EMG, non-negative matrix factorization and our recently proposed rectified latent variable model will be used to extract muscle synergy indices, which, from our preliminary results (see below), contain predictive stroke recovery information. From the EEG and EMG, coherence between these two signals (cortico- muscular coherence) and that between EEG and muscle synergy activations (cortico-synergy coherence) will be computed through spectral analysis. From the motion capture data, movement parameters such as joint motion range can be extracted with standard methods. All parameters above will be used as predictors in phase 2.

Phase 2: AI Fusion Model. Once the investigators have extracted the predictors from each modality, the investigators will develop a fusion model, one for each treatment group and each clinical score, that integrates these A0 predictor inputs for a prediction of the A1 and A2 scores . Since the investigators do not have prior information on the suitability of the different methods to be used in fusion models, the investigators will evaluate the performance of various models. Artificial neural networks with meta-learning will be used for their capacity to learn from a rich set of data features. Their performance will be benchmarked against other models such as logistic regression, Bayesian methods, and random forests, methods that are advantageous for smaller datasets such as ours. For each treatment group, the fusion model will be trained on the phase-1 predictors with the labelled data from the 100 subjects as inputs to predict the score improvements at A1 and A2.

Realistically, the investigators anticipate that our final database will have occasional missing data points. The investigators will employ mutual information-based imputation techniques to estimate missing heterogenous values, thereby making full use of the available data and preventing biases in model training. Sensitivity analyses will be conducted to assess the impact of the missing data on model predictions, thereby ensuring the reliability of our findings.

Through the entire system construction process, the investigators will utilize and compare different AI algorithms for phase-1 feature extractions and phase-2 fusion. The models and approaches employed will be iteratively refined based on test performance metrics and clinical feedback. Historical data will be utilized to validate the models through retrospective assessment of the effectiveness of the recommended interventions in previous clinical scenarios.

Additional Phase 3: Building Decision-making Framework. For every subject, by comparing the phase-2 outcome predictions across the treatment-specific models, one may already decide on an ideal intervention for the subject simply by selecting the treatment whose model yields the best A2 improvement. But this selection process is not transparent, because the fusion models do not explicitly indicate how the many predictors interact to lead the models to collectively arrive at the recommended treatment. To enhance the AI system's explanability, the investigators will implement a phase 3 for constructing an explicit decision-making framework that guides intervention selection, one analogous to the clinically successful PREP decision-tree algorithm of Stinear et al. A classifier will be trained with the phase-1 predictors and the phase-2 score predictions of all subjects (N=400) serving as inputs, and the ranked intervention preferences inferred from phase-2 outcome comparison as outputs. The trained classifier can serve as a decision support tool that reveals the most parsimonious set of evaluations needed for reaching decisions, and provides transparent reasoning behind its recommendations, thereby enhancing our understanding of why particular subjects are assigned to each treatment. To maximize interpretability, the investigators will implement decision-tree algorithms such as the random forests, which are capable of discerning complex, nonlinear relationships among the variables.

03

Conditions studied

  • Acute Stroke Intervention
  • Acute Stroke
  • Acute Ischemic Stroke

Browse trials for

Keywords

  • stroke
  • motor neuroscience
  • MRI
  • rehabilitation
  • muscle coordination
  • electromyography
  • Artificial intelligence
  • Transcranial Magnetic Stimulation
  • neuroimaging
  • Proteomics
  • Metabolomics
  • Genomics
  • Epigenomics
  • Acupuncture
  • biomarkers
  • muscle synergies
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 400 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

IInclusion Criteria:

  • Age 65-80
  • 1-6 months after onset of a first-time unilateral stroke rostral to midbrain
  • Moderate-to-severe motor impairment of one upper limb (Fugl-Meyer Assessment for Upper Extremity of 10-50 out of 66);
  • Able to provide written ;
  • Detectable electromyographic (EMG) activities in flexor digitorum-flexor carpi radialis and extensor digitorum-extensor carpi ulnaris muscle groups, with EMG from each muscle group exceeding 3 standard deviations above baseline mean. This last criterion is essential for successful NMES training

Exclusion Criteria:

  • Unconscious or bed-bound;
  • Uncontrollable diabetes;
  • Anticipated non-adherence to treatment schedule;
  • On cardiac pacemaker;
  • Other severe comorbidities (heart/kidney failure, deranged liver function).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
400 participants (estimated)

Study arms

  • Active comparator
    Rehabilitation Control Group

    Subacute stroke survivors in this group, patients will receive usual rehab care only.

    Other: control group

  • Active comparator
    Acupuncture Group

    Subacute stroke survivors in this group, patients will receive usual rehab care plus acupuncture

    Other: Acupuncture

  • Active comparator
    Robotic Training Group

    Subacute stroke survivors in this group, patients will receive usual rehab care plus robotic training

    Device: Robotic Training

  • Active comparator
    NMES Group

    Subacute stroke survivors in this group, patients will receive usual rehab care plus Neuromuscular Electrical Stimulation (NMES)

    Device: Neuromuscular Electrical Stimulation Group

Interventions

  • OtherAcupuncture

    Patients will receive 12 weeks of acupuncture with 3 half-hour sessions weekly. Acupoints will include (1) a basic formula of 8 Bo's abdomen acupoints (paretic side, 0.5cm depth vertically) \[66\]; (2) 12 conventional acupoints (bilateral, opposite to paretic side first, 1-4 cm depth vertically) \[67\]; and (3) 3 scalp acupoints (opposite to paretic side, 0.5-cm depth at 15-30 degrees) \[68\]At most 3 additional supplementary acupoints will be included, depending on the clinician's professional judgement. Sterile needles will be used after skin disinfection. Manual rotating manipulation \[69\] will be performed every 10 minutes on the conventional acupoints to achieve De-qi sensation \[70\]. Abdomen and scalp acupoints do not require De-qi. Subjects will be monitored throughout the course of therapy with face-to-face assessments by blinded and trained clinicians after 0, 4, 8, 12 weeks of intervention. Clinical scales will also be recorded at 0 (A0), 8 (A½), and 12 weeks (A1).

  • Othercontrol group

    Subjects in this group will receive the typical post-stroke care offered to stroke survivors of Hong Kong. This care emphasizes restoring function and independence through a comprehensive approach. Physical therapy focuses on improving mobility with exercises and training; occupational therapy helps patients relearn essential daily living skills, facilitating a smooth transition back to everyday life. Speech therapy is integral for addressing communication challenges, and psychological support is provided to help patients manage the emotional impact of stroke. All subjects will receive the above care for 8 weeks (≥3 hourly sessions per week). Clinical scales will be recorded at 0 (A0), 4 (A½), and 8 weeks (A1).

  • DeviceRobotic Training

    For this treatment group, CMC (corticomuscular coherence)-EMG-triggered control will assist wrist extension with hand open and wrist flexion with hand close alternately by mechanical pneumatic support \[60\]. During wrist-hand extension, the pneumatic fingers will assist a hand-open motion with constant inflation till the inner pressure reaches 90kPa; during the wrist-hand flexion, the pneumatic fingers will deflate constantly to assist a hand-close motion. To trigger ENMS assistance, two criteria must be met: (1) the average EMGs of target muscles exceed a pre-defined threshold, and (2) a significant CMC peak value with peak frequency in the beta band is captured. Here, the target muscle groups will be the extensor digitorum and extensor carpi ulnaris (ED-ECU) and flexor digitorum and flexor carpi radialis (FD-FCR), and the EMG and CMC will be evaluated during sustained contraction of these muscles over a 3-sec window.

  • DeviceNeuromuscular Electrical Stimulation Group

    For this treatment group, constant NMES (70V, 40Hz, 0-300µs square wave bursts \[63\]) will be delivered to the ED-ECU and FD-FCR muscles to assist in wrist-hand extension and flexion, respectively. The pulse width of NMES will be individually adjusted to achieve the maximum muscle contraction with the minimum stimulation intensity. The control strategy of CMC-EMG-triggered NMES will be the same as that used in the robot.

07

What researchers measure

Primary outcomes

  1. Surface EMG Recordings

    Surface EMG electrodes may be conveniently used to record myoelectric activities of multiple muscles during voluntary movement. This data can reveal the muscle coordination patterns utilized by the motor system for control. We have previously shown that muscle synergies, building blocks of muscle coordination decomposed from EMG using machine learning, may serve as markers of post-stroke functional assessment and prognosis. Here, we will record EMG from 16 affected-side muscles during 8-10 activities of daily living.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

  2. Kinematic recordings

    We will utilize motion capture technology to analyze stroke patients' movements by attaching reflective markers to their bodies. This setup will allow us to record their performance during 8 to 10 activities of daily living. The collected data will enable us to evaluate joint angles and movement patterns, providing insights into functional capabilities and informing rehabilitation strategies.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

  3. Cortico-muscular Coherence (CMC) from Electroencephalography (EEG) and EMG

    The CMC is a measure, derived from concurrent EEG and EMG during movement, that quantifies the overall capacity of the cortex to coordinate activities of multiple muscles. After stroke, the CMC between different brain regions and muscles are altered. Given that the structural connectome may predict recovery potential, it is likely that CMC should carry some predictive power. We will record EEG (64 channels) during the EMG assessment described above. The CMC between each EEG channel and each muscle may serve as inputs to the prediction system.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

Secondary outcomes

  1. Fugl-Meyer Assessment for Upper Extremity

    The Fugl-Meyer Assessment (FMA) for Upper Extremity is a standardized test used to evaluate motor function, sensation, and joint function in individuals with neurological conditions, particularly after a stroke. It assesses voluntary movements of the shoulder, elbow, wrist, and fingers, as well as sensory capabilities. Scoring ranges from 0 (no function) to 66 (full function), helping to identify impairments and monitor recovery progress in rehabilitation settings.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

  2. Modified Tardieu Scale

    The Modified Tardieu Scale is a clinical tool used to assess spasticity in individuals with neurological conditions. It measures the resistance of a muscle to passive stretch at different velocities, providing insights into the severity of spasticity. The scale includes observations of muscle reaction during slow and fast stretches, rating the response from 0 (no resistance) to 4 (very strong resistance). This assessment helps guide treatment and rehabilitation strategies for managing spasticity.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

  3. National Institutes of Health Stroke Scale

    The National Institutes of Health Stroke Scale (NIHSS) is a clinical assessment tool used to evaluate the severity of stroke symptoms. It consists of 15 items that assess functions such as consciousness, vision, movement, speech, and sensation. Each item is scored, with higher total scores indicating more severe impairment. The NIHSS is essential for diagnosing stroke, guiding treatment decisions, and predicting patient outcomes.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

  4. Brunnstrom Stages

    The Brunnstrom Stages are a framework for understanding the progression of motor recovery after a stroke. Developed by Signe Brunnstrom, the stages range from 1 to 7, describing the evolution from flaccidity (Stage 1) to the re-emergence of coordinated movement and normal function (Stage 7). Each stage reflects specific patterns of muscle tone and voluntary movement, helping clinicians plan rehabilitation strategies and track recovery progress.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

  5. Wolf Motor Function Test

    The Wolf Motor Function Test (WMFT) is a standardized assessment used to evaluate upper extremity motor function in individuals after a stroke or neurological injury. It measures the speed and quality of performing various tasks involving hand and arm movements, such as reaching, grasping, and manipulation. The test includes timed tasks and a functional score, providing insights into motor recovery and guiding rehabilitation interventions.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

  6. Barthel Index

    The Barthel Index is a measure of an individual's ability to perform activities of daily living (ADLs) independently. It assesses ten specific tasks, including feeding, bathing, dressing, and mobility, assigning scores that reflect the level of assistance required. The total score ranges from 0 (completely dependent) to 100 (fully independent), making it a valuable tool for evaluating functional status and progress in rehabilitation, particularly after stroke or other disabilities.

    Time frame: From Pre-assessment stages (A0) to follow up sessions (A2), the whole time frame will be within 6 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 29 months is close to that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Feb 14, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06828679
Collaborators
The Hong Kong Polytechnic University, City University of Hong Kong, Hong Kong Baptist University, The University of Western Australia
Responsible party
Cheung Chi Kwan Vincent (Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Feb 14, 2025
Start date
Jul 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Dec 22, 2025

Study contacts

Yat Sing Kelvin Lau, MSc
Contact
yatsingkelvinlau@cuhk.edu.hk
85296363365

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion